Avalon Trust’s Bristol-Myers Squibb BMY Stock Holding History

Avalon Trust’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30K	Hold	521	–	–	﹤0.01%	334
2026 Q1	$31.6K	Hold	521	–	–	﹤0.01%	331
2025 Q4	$28.1K	Sell	521 -1,344	-72%	-$64.7K	﹤0.01%	333
2025 Q3	$84.1K	Buy	1,865 +19	+1%	+$887	0.01%	251
2025 Q2	$85.5K	Sell	1,846 -651	-26%	-$32K	0.01%	211
2025 Q1	$152K	Buy	2,497 +1,976	+379%	+$115K	0.01%	151
2024 Q4	$29.5K	Hold	521	–	–	﹤0.01%	272
2024 Q3	$27K	Hold	521	–	–	﹤0.01%	250
2024 Q2	$21.6K	Hold	521	–	–	﹤0.01%	259
2024 Q1	$28.3K	Hold	521	–	–	﹤0.01%	250
2023 Q4	$26.7K	Hold	521	–	–	﹤0.01%	248
2023 Q3	$30.2K	Hold	521	–	–	﹤0.01%	210
2023 Q2	$33.3K	Hold	521	–	–	﹤0.01%	224
2023 Q1	$36.1K	Buy	+521	New	+$36.7K	﹤0.01%	216

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avalon Trust's BMY Position: Q2 2026 in Review

Avalon Trust held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 521 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #334.

Avalon Trust first reported a position in BMY in Q1 2023 and has held it in 14 quarters since. The position peaked at $152K in Q1 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Avalon Trust held 521 shares of Bristol-Myers Squibb worth $30K as of Q2 2026.
Avalon Trust left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up ﹤0.01% of Avalon Trust's portfolio in Q2 2026, its #334 holding.
Avalon Trust first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 14 quarters since.
Avalon Trust's Bristol-Myers Squibb position peaked at $152K in Q1 2025.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Avalon Trust's 13F filing for Q2 2026, filed 6 Aug 2026.